Dr Reddy's launches anti-diabetic foot ulcers drug Plermin

Dr. Reddy's Laboratories has launched India's first drug on diabetic foot ulcers. The product 'Plermin' (generic name: Recombinant Human Platelet Derived Growth Factor - rhPDGF) will be available as a gel in 7.5 gm and 15 gm tubes.

According to a release issued by Dr. Reddy's to the BSE, Plermin is the first and only therapeutic intervention for the treatment of diabetic foot ulcers, which are the leading cause of non-traumatic amputations in India.

rhPDGF is one of the most widely studied biological growth factors and has shown to promote formation of granulation tissue, thereby enhancing the rate & speed of healing in diabetic foot ulcers, the release said.

Satish Reddy, MD and COO, of Dr. Reddy's said, "The launch of Plermin marks a significant step in the area of foot care and reinforces our commitment to those patients who develop foot ulcers due to neuropathy. PLERMIN, the first rhPDGF in India, is the only growth factor that is widely studied and proven to offer faster healing of ulcers. The introduction of Plermin in India coincides with the theme of World Diabetes Day and underlines the important role of foot care in reducing amputations."